Lipocine announces its partner received fda acceptance of nda resubmission for tlando®

Salt lake city, feb. 3, 2022 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a clinical-stage biopharmaceutical company focused on developing innovative products for metabolic and endocrine disorders, today announced that antares pharma, inc. issued a press release announcing that the u.s. food and drug administration ("fda") has accepted its new drug application ("nda") resubmission for tlando® (testosterone undecanoate).  the fda designated the nda as a class 1 resubmission with a two-month review goal period and set a target action date of march 28, 2022, under the prescription drug user fee act (pdufa).
LPCN Ratings Summary
LPCN Quant Ranking